Luks, Andrew M. Clinician's corner: travel to high altitude following solid organ transplantation. High Alt Med Biol. 17:147–156, 2016.—As they regain active lifestyles following successful organ transplantation, transplant recipients may travel to high altitude for a variety of activities, including skiing, climbing, and trekking. This review is intended to provide information for medical providers who may encounter transplant patients seeking advice before planned high altitude travel or care for medical issues that develop during the actual sojourn. There is currently limited information in the literature about outcomes during high-altitude travel following solid organ transplantation, but the available evidence suggests that the physiologic responses to hypobaric hypoxia are comparable to those seen in nontransplanted individuals and well-selected transplant recipients with no evidence of organ rejection can tolerate ascents as high as 6200 m. All transplant recipients planning high-altitude travel should undergo pretravel assessment and counseling with an emphasis on the recognition, prevention, and treatment of altitude illness, as well as the importance of preventing infection and limiting sun exposure. Transplant recipients can use the standard medications for altitude illness prophylaxis and treatment, but the choice and dose of medication should take into account the patient's preexisting medication regimen and current renal function. With careful attention to these and other details, the healthy transplant recipient can safely experience the rewards of traveling in the mountains.
Get full access to this article
View all access options for this article.
References
1.
AnglicheauD, FlamantM, SchlagterMH, MartinezF, CassinatB, BeauneP, LegendreC, ThervetE. (2003). Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant, 18: 2409–2414.
2.
AsklingHH, and DalmVA. (2014). The medically immunocompromised adult traveler and pre-travel counseling: Status quo 2014. Travel Med Infect Dis, 12:219–228.
3.
BartschP, MairbaurlH, SwensonER, and MaggioriniM. (2003). High altitude pulmonary oedema. Swiss Med Wkly, 133:377–384.
4.
BartschP, and SwensonER. (2013). Clinical practice: Acute high-altitude illnesses. N Engl J Med, 368:2294–2302.
5.
BerendsohnS. (1962). Hepatic function at high altitudes. Arch Intern Med, 109:256–264.
6.
BesarabA, CaroJ, JarrellBE, FrancosG, and ErslevAJ. (1987). Dynamics of erythropoiesis following renal transplantation. Kidney Int, 32:526–536.
7.
BoggildAK, SanoM, HumarA, SalitI, GilmanM, and KainKC. (2004). Travel patterns and risk behavior in solid organ transplant recipients. J Travel Med, 11:37–43.
8.
Botella de MagliaJ, and Fuster EscrivaA. (2007). Lung transplanted patient climbing a mountain higher than 4,000 m. Comparison with healthy climbers. Med Clin (Barc), 129:339–34.
9.
BuettnerKJK. (1969). The effect of natural sunlight on human skin. In: The Biologic Effects of Ultraviolet Radiation, with Special Emphasis on the Skin. UrbachF, ed. Pergamon Press, Oxford. Pp. 237–249.
10.
CannomDS, RiderAK, StinsonEB, and HarrisonDC. (1975). Electrophysiologic studies in the denervated transplanted human heart. II. Response to norepinephrine, isoproterenol and propranolol. Am J Cardiol, 36:859–866.
11.
ChenSC, SlavinMA, SorrellTC. (2011). Echinocandin antifungal drugs in fungal infections: a comparison. Drugs, 71: 11–41.
12.
ChenSL, ZhangH, XieDJ, ZhangJ, ZhouL, RothmanAM, and StoneGW. (2015). Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: Phase II results from the pulmonary artery denervation-1 study. Circ Cardiovasc Interv, 8:e002837.
13.
CiarkaA, CuylitsN, VachieryJL, LamotteM, DegauteJP, NaeijeR, and van de BorneP. (2006). Increased peripheral chemoreceptors sensitivity and exercise ventilation in heart transplant recipients. Circulation, 113:252–257.
14.
CottsWG, and OrenRM. (1997). Function of the transplanted heart: unique physiology and therapeutic implications. Am J Med Sci, 314:164–172.
DresserGK, SpenceJD, BaileyDG. (2000). Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet, 38: 41–57.
17.
GillJS, TonelliM, MixCH, and PereiraBJ. (2003). The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol, 14:1636–1642.
18.
HackettPH, and RoachRC. (2004). High altitude cerebral edema. High Alt Med Biol, 5:136–146.
19.
HillebrandtD. (2003). Six selected cases from a year's experience as advisory doctor to a commercial mountaineering expedition company. High Alt Med Biol, 4:93–98.
20.
IngvarA, SmedbyKE, LindelofB, FernbergP, BelloccoR, TufvesonG, HoglundP, and AdamiJ. (2010). Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol Dial Transplant, 25:2764–2771.
21.
IzzoAA, ErnstE. (2009). Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs, 69:1777–1798.
22.
JurgensG, ChristensenHR, BrosenK, SonneJ, LoftS, and OlsenNV. (2002). Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. Clin Pharmacol Ther, 71:214–220.
23.
KotloffRM, and KeshavjeeS. (2016). Lung transplantation. In: Murray and Nadel's Textbook of Respiratory Medicine. BroaddusVC and MasonRJet al., eds. Elsevier Saunders, Philadelphia. pp. 1832–1849.
24.
KottonCN, RyanET, and FishmanJA. (2005). Prevention of infection in adult travelers after solid organ transplantation. Am J Transplant, 5:8–14.
25.
LuksAM. (2009a). Can patients with pulmonary hypertension travel to high altitude?. High Alt Med Biol, 10:215–219.
26.
LuksAM. (2009b). Should travelers with hypertension adjust their medications when traveling to high altitude?. High Alt Med Biol, 10:11–15.
27.
LuksAM. (2012). Clinician's corner: What do we know about safe ascent rates at high altitude?. High Alt Med Biol, 13:147–152.
28.
LuksAM. (2014). Physiology in medicine: A physiologic approach to prevention and treatment of acute high altitude illnesses. J Appl Physiol (1985), 118:509–519.
29.
LuksAM, McIntoshSE, GrissomCK, AuerbachPS, RodwayGW, SchoeneRB, ZafrenK, and HackettPH. (2014). Wilderness medical society practice guidelines for the prevention and treatment of acute altitude illness: 2014 Update. Wilderness Environ Med, 25:S4–S14.
30.
LuksAM, SchoeneRB, and SwensonER. (2016). High altitude. In: Murray and Nadel's Textbook of Respiratory Medicine. BroaddusVC and MasonRJet al., eds. Elsevier Saunders, Philadelphia. pp. 1367–1384.
31.
LuksAM, and SwensonER. (2008). Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. Chest, 133:744–755.
32.
MarcenR, MoralesJM, Fernandez-RodriguezA, CapdevilaL, PallardoL, PlazaJJ, CuberoJJ, PuigJM, Sanchez-FructuosoA, AriasM, AlperovichG, and SeronD. (2010). Long-term graft function changes in kidney transplant recipients. NDT Plus, 3:ii2–ii8.
33.
McCarthyAE, and MilenoMD. (2006). Prevention and treatment of travel-related infections in compromised hosts. Curr Opin Infect Dis, 19:450–455.
34.
McNallyP, MistryN, IdleJ, WallsJ, and FeehallyJ. (1989). Calcium channel blockers and cyclosporine metabolism. Transplantation, 48:1071.
35.
MilledgeJS, and CotesPM. (1985). Serum erythropoietin in humans at high altitude and its relation to plasma renin. J Appl Physiol, 59:360–364.
36.
MudigondaT, LevenderMM, O'NeillJL, WestCE, PearceDJ, and FeldmanSR. (2013). Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: A review of single- and multicenter retrospective studies from 2006 to 2010. Dermatol Surg, 39:345–364.
37.
MurdochDR. (1995). Symptoms of infection and altitude illness among hikers in the mount everest region of Nepal. Aviat Space Environ Med, 66:148–151.
38.
MuzaSR, BeidlemanBA, and FulcoCS. (2010). Altitude preexposure recommendations for inducing acclimatization. High Alt Med Biol, 11:87–92.
39.
PirenneJ, Van GelderF, KharkevitchT, NevensF, VerslypeC, PeetermansWE, KitadeH, VanheesL, DevosY, HauserM, HamoirE, Noizat-PirenneF, and PirotteB. (2004). Tolerance of liver transplant patients to strenuous physical activity in high-altitude. Am J Transplant, 4:554–560.
40.
PughLG, GillMB, LahiriS, MilledgeJS, WardMP, and WestJB. (1964). Muscular exercise at great altitudes. J Appl Physiol, 19:431–440.
41.
RobinED, TheodoreJ, BurkeCM, OesterleSN, FowlerMB, JamiesonSW, BaldwinJC, MorrisAJ, HuntSA, VankesselA, et al. (1987). Hypoxic pulmonary vasoconstriction persists in the human transplanted lung. Clin Sci (Lond), 72:283–287.
42.
SandersMH, OwensGR, SciurbaFC, RogersRM, ParadisIL, GriffithBP, and HardestyRL. (1989). Ventilation and breathing pattern during progressive hypercapnia and hypoxia after human heart-lung transplantation. Am Rev Respir Dis, 140:38–44.
StreitM, GoggelmannC, DehnertC, BurhenneJ, RiedelKD, MenoldE, MikusG, BartschP, and HaefeliWE. (2005). Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). Eur J Clin Pharmacol, 61:39–46.
47.
SuhKS, KimT, YiNJ, and HongG. (2015). Preparation for high altitude expedition and changes in cardiopulmonary and biochemical laboratory parameters with ascent to high altitude in transplant patients and live donors. Clin Transplant, 29:1013–1020.
48.
SunCH, WardHJ, PaulWL, KoyleMA, YanagawaN, and LeeDB. (1989). Serum erythropoietin levels after renal transplantation. N Engl J Med, 321:151–157.
49.
SwensonER, DuncanTB, GoldbergSV, RamirezG, AhmadS, and SchoeneRB. (1995). Diuretic effect of acute hypoxia in humans: relationship to hypoxic ventilatory responsiveness and renal hormones. J Appl Physiol, 78:377–383.
50.
TabbaraKF, Al-FaisalZ, Al-RashedW. (1998). Interaction between acetazolamide and cyclosporine. Arch Opthalmol, 116: 832–833.
51.
van AdrichemEJ, SiebelinkMJ, RottierBL, DillingJM, KuikenG, van der SchansCP, and VerschuurenEA. (2015). Tolerance of organ transplant recipients to physical activity during a high-altitude expedition: Climbing mount Kilimanjaro. PLoS One, 10:e0142641.
52.
VarisT, KivistoKT, BackmanJT, NeuvonenPJ. (2000). The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal suppressant effect. Clin Pharmacol Ther, 68: 487–494.
53.
WagnerPD. (2000). Reduced maximal cardiac output at altitude—mechanisms and significance. Respir Physiol, 120:1–11.
54.
WestJB, SchoeneRB, LuksAM, and MilledgeJS. (2013). High Altitude Medicine and Physiology. CRC Press: Taylor & Francis Group, Boca Raton.
55.
WilliamsTJ, and McKennaMJ. (2012). Exercise limitation following transplantation. Compr Physiol, 2:1937–1979.
56.
ZwaldFO, and BrownM. (2011). Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part II. Management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol, 65:263–279.
